Search our Database of Scientific Publications and Authors

I’m looking for a

    4430 results match your criteria Urticaria Chronic

    1 OF 89

    Serum Sickness-like Reaction in a Pediatric Patient using Omalizumab for Chronic Spontaneous Urticaria.
    Pediatr Allergy Immunol 2018 Feb 14. Epub 2018 Feb 14.
    Department of Pediatrics, Division of Pulmonary, Allergy and Sleep Medicine, Indiana University School of Medicine.
    Omalizumab has been approved for chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in children 12 years and older. Two treatment doses of omalizumab are available: 150 mg or 300 mg every 4 weeks. While 150 mg has been shown to be effective, most patients with CIU/CSU require 300 mg every 4 weeks to achieve symptom improvement. Read More

    Chronic inducible urticaria: a systematic review of treatment options.
    J Allergy Clin Immunol 2018 Feb 10. Epub 2018 Feb 10.
    Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology, Venerology and Allergy. Electronic address:
    Background: Chronic inducible urticaria (CindU) is a condition characterized by the appearance of recurrent wheals, angioedema or both, as a response to specific and reproducible triggers.

    Objective: To systematically assess the evidence on the efficacy and safety of treatment options for CindU. Results were used to inform the 2017 update of "The EAACI/GALEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of Urticaria. Read More

    Posttraumatic stress disorder, emotional suppression and psychiatric co-morbidity in patients with chronic idiopathic urticaria: a moderated mediation analysis.
    J Ment Health 2018 Feb 12:1-8. Epub 2018 Feb 12.
    a Department of Educational Psychology, Faculty of Education , The Chinese University of Hong Kong , Shatin NT , Hong Kong , and.
    Background: There is evidence suggesting that posttraumatic stress disorder (PTSD) symptom severity and CIU severity are linked and partially mediated by the high-anxious defense mechanism. What is unclear is whether emotional suppression, as a defense serving the opposite purpose for high-anxious defense, can also act as a mediator and whether this mediational effect is partly influenced by time since trauma and trauma type.

    Aims: To investigate whether emotional suppression mediated the links between PTSD and CIU symptom severities, and PTSD and psychiatric co-morbid symptom severities. Read More

    Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence.
    Expert Opin Biol Ther 2018 Feb 16:1-24. Epub 2018 Feb 16.
    e Matrix45 , Tucson , AZ , USA.
    Introduction: Chronic idiopathic/spontaneous urticaria (CIU/CSU) is a dermatological condition characterized by itchy wheals and/or angioedema of continuous or intermittent duration of ≥6 weeks with a high burden of disease and impact on quality of life. Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of IgE to high affinity receptors, and is approved for the CIU/CSU indication. The objective of this systematic review was to evaluate and synthesize the evidence on the real-world effectiveness of omalizumab in CIU/CSU in daily clinical practice. Read More

    Biomarkers for evaluation of mast cell and basophil activation.
    Immunol Rev 2018 Mar;282(1):114-120
    Division of Allergy and Clinical Immunology, Department of Medicine, University of Salerno, Salerno, Italy.
    Mast cells and basophils play a pathogenetic role in allergic, inflammatory, and autoimmune disorders. These cells have different development, anatomical location and life span but share many similarities in mechanisms of activation and type of mediators. Mediators secreted by mast cells and basophils correlate with clinical severity in asthma, chronic urticaria, anaphylaxis, and other diseases. Read More

    The role and relevance of mast cells in urticaria.
    Immunol Rev 2018 Mar;282(1):232-247
    Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
    This review presents evidence that the skin mast cell, in particular the MCsubtype, is the primary effector cell in urticaria. Mast cells are located in the upper dermis, the ideal situation for wheal formation and sensory nerve stimulation. Increased numbers of mast cells are found in both lesional and non-lesional skin in CSU and inducible urticaria. Read More

    Colchicine in dermatology: A review.
    Australas J Dermatol 2018 Feb 12. Epub 2018 Feb 12.
    Department of Dermatology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
    Colchicine is an anti-inflammatory agent that has been used for decades for the treatment of various diseases including gout, familial Mediterranean fever and pericarditis and in recent years for dermatological indications including chronic urticaria, cutaneous vasculitis and psoriasis. Despite its efficacy in various cutaneous diseases, the use of colchicine may be limited by concerns over its side-effects and the potential for toxicity. This article reviews the current literature on the pharmacology of colchicine and its clinical applications in dermatology. Read More

    Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States.
    Dermatol Ther (Heidelb) 2018 Feb 10. Epub 2018 Feb 10.
    Herbert Wertheim School of Medicine, Florida International University, Miami, FL, USA.
    Introduction: Few studies have described chronic idiopathic/spontaneous urticaria (CIU/CSU) healthcare burden in adults, while this information remains largely unknown in children. We aimed to describe treatment patterns, healthcare resource utilization (HRU), and costs in CIU/CSU pediatric patients, as well as to compare HRU and costs in CIU/CSU and CIU/CSU-free pediatric patients.

    Methods: Medicaid claims from four states (09/01/2013-03/31/2016) were used to identify patients less than 12 years old. Read More

    Thyroid function and thyroid autoantibodies in patients with chronic spontaneous urticaria.
    Postepy Dermatol Alergol 2017 Dec 31;34(6):566-572. Epub 2017 Dec 31.
    Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.
    Introduction: Chronic urticaria (CU) is a skin disease caused by autoantibodies against high affinity immunoglobulin E (IgE) receptor and against IgE. It is characterized by hives, erythematous wheals and redness present minimum twice a week for at least 6 weeks. It is observed that there is a strong association between CU and autoimmune diseases, such as autoimmune thyroiditis (AT). Read More

    A Case of Intraoperative Anaphylaxis Caused by Bovine-Derived Thrombin.
    Allergy Asthma Immunol Res 2018 Mar;10(2):184-186
    Division of Allergy and Immunology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
    Intraoperative bovine-derived topical thrombin is still widely used for hemostasis during surgery. A 38-year-old woman with chronic spontaneous urticaria was referred to the orthopedic surgery department for herniated disk and myelopathy. During the first stage of operation, bovine-derived thrombin powder soaked in Gelfoam was used as a hemostatic aid. Read More

    Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States.
    J Manag Care Spec Pharm 2017 Dec 19:1-11. Epub 2017 Dec 19.
    4 University of Rochester Medical Center, Rochester, New York.
    Background: Omalizumab is indicated for the management of chronic idiopathic urticaria (CIU) in patients aged 12 years or older with persistent hives that are not adequately controlled by H1 antihistamines. While its safety and efficacy in CIU patients have been evaluated in multiple clinical trials, real-world use of omalizaumab in CIU has not been well characterized.

    Objective: To assess demographics, clinical characteristics, and treatment patterns of CIU patients who initiated omalizumab to better understand the usage of this agent in CIU management in the real world. Read More

    Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria.
    Int J Dermatol 2018 Feb 5. Epub 2018 Feb 5.
    Allergy Department, "Sotiria" General Hospital, Athens, Greece.
    Background: Previous clinical trials have demonstrated the efficacy and safety of the anti-IgE monoclonal antibody omalizumab in chronic spontaneous urticaria (CSU) not responding to antihistamine treatment. The primary aim of our study was to describe the response patterns of patients with refractory CSU treated with omalizumab in a real-world clinical setting.

    Methods: A retrospective analysis of medical records of 20 patients with refractory CSU was performed. Read More

    Establishing a Safe Administration of ASA in Cardiovascular Patients with Nonsteroidal Anti-Inflammatory Drug Hypersensitivity with Skin and/or Respiratory Involvement.
    Int Arch Allergy Immunol 2018 Jan 26. Epub 2018 Jan 26.
    Sabah Al Ahmed Cardiac Center, Ministry of Health, Kuwait City, Kuwait.
    Background: A history of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity with cross-intolerance to several drugs is common in some patients with coronary artery disease. We present a series of patients with acute coronary syndrome undergoing ASA desensitization prior to a possible stent to evaluate the short- and long-term efficacy and safety. The aim was to evaluate the outcomes of an ASA desensitization protocol developed by our center based on the guidelines proposed by the EAACI drug allergy expert recommendations. Read More

    Chronic spontaneous urticaria in children - a systematic review on interventions and comorbidities.
    Pediatr Allergy Immunol 2018 Feb 2. Epub 2018 Feb 2.
    University François Rabelais Tours, CHRU Tours, Department of Dermatology, 37044, Tours Cedex 9, France.
    Background: Chronic spontaneous urticaria (CSU) is not frequent in children. Management guidelines have been developed for adults and randomized controlled trials (RCTs) included teenagers aged 12 to 18, but data for children under age 12 are limited. We performed a systematic review to assess comorbidities in children < 12 years old with CSU and the efficacy and safety of treatments. Read More

    Localized salt-dependent aquagenic urticaria, a rare subtype of urticaria: a case report.
    Eur Ann Allergy Clin Immunol 2017 Nov 20. Epub 2017 Nov 20.
    Immunoallergy Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
    Summary: Aquagenic urticaria (AU) is a rare form of chronic inducible urticaria elicited by water at any temperature. We describe the case of a 25-year-old atopic woman who presented to our unit with a 4-year history of recurrent urticarial rashes, highly pruritic, confined to the neck and lower part of the face, occurring solely on contact with sea water. The lesions were reproduced by challenge tests with aqueous 3. Read More

    Restoration of aspirin tolerance following omalizumab treatment in a patient with chronic spontaneous urticaria.
    Eur Ann Allergy Clin Immunol 2017 Nov 30. Epub 2017 Nov 30.
    Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italy.
    Summary: Up to 30% of cases of chronic spontaneous urticaria (CSU) are exacerbated by COX-1 inhibit-ing nonsteroidal anti-inflammatory drugs (NSAID); this clinical picture is termed NECD (NSAID-exacerbated cutaneous disease). On the other hand, multiple NSAID hypersensitivity may occur in the absence of an underlying CSU also, a situation that is termed NIUA (NSAID-induced urticaria / angioedema). The present study reports a case of multiple NSAID hypersensitivity that occurred in a man much before he developed severe CSU. Read More

    The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria.
    Int J Dermatol 2018 Jan 30. Epub 2018 Jan 30.
    Division of Dermatology, Department of Medicine, Faculty of Medicine, Srinagarind Hospital Medical School, Khon Kaen University, Khon Kaen, Thailand.
    Background: An increase in dosages up to fourfold of second generation antihistamines is recommended for recalcitrant chronic spontaneous urticaria (CSU). No regimen guidelines about dose de-escalation, however, are mentioned once the disease is controlled.

    Objective: To demonstrate the treatment outcomes and dose reduction in desloratadine assessed using the urticarial activity score over 7 consecutive days. Read More

    The functional and structural alterations of the striatum in chronic spontaneous urticaria.
    Sci Rep 2018 Jan 29;8(1):1725. Epub 2018 Jan 29.
    Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA 02129, USA.
    The brain has long been known to be the regulation center of itch, but the neuropathology of chronic itch, such as chronic spontaneous urticaria (CSU), remains unclear. Thus, we aimed to explore the brain areas involved in the pathophysiology of CSU in hopes that our results may provide valuable insights into the treatment of chronic itch conditions. 40 CSU patients and 40 healthy controls (HCs) were recruited. Read More

    Skin Testing for Suspected Iodinated Contrast Media Hypersensitivity.
    J Allergy Clin Immunol Pract 2018 Jan 19. Epub 2018 Jan 19.
    Exploration des Allergies, Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France. Electronic address:
    Background: The management of iodinated contrast medium (ICM) hypersensitivity has been a matter of debate. Skin testing to identify a subgroup of ICM allergic patients has been proposed, in addition to complete avoidance, provocation testing, or premedication.

    Objective: The objective of this study was to assess the negative predictive value (NPV) of skin testing for ICM. Read More

    Development and Validation of the Cholinergic Urticaria Quality of Life Questionnaire: CholU-QoL.
    Clin Exp Allergy 2018 Jan 25. Epub 2018 Jan 25.
    Charité - Universitätsmedizin Berlin, Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Allergy, Germany.
    Background: Cholinergic urticaria (CholU), a common form of chronic inducible urticaria, is characterized by itchy wheals that occur in response to physical exercise or passive warming. CholU patients frequently exhibit a high burden of disease. As of yet, no specific instrument is available to assess their disease-related quality of life (QoL) impairment. Read More

    Omalizumab updosing allows disease activity control in refractory patients with chronic spontaneous urticaria.
    Br J Dermatol 2018 Jan 24. Epub 2018 Jan 24.
    Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma Barcelona (UAB), Dermatology.
    Omalizumab has been shown to be a very effective drug in chronic spontaneous urticaria (CSU) improving patients' quality of life.Phase III clinical trials ASTERIA I/II and GLACIAL showed respectively 58.8-52. Read More

    Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study.
    Am J Clin Dermatol 2018 Jan 24. Epub 2018 Jan 24.
    Charité-Universitätsmedizin Berlin, Berlin, Germany.
    Background: The Urticaria Activity Score summed over 7 days (UAS7) assesses the itch severity and hive count in chronic spontaneous urticaria (CSU) using once- or twice-daily diary-based documentation.

    Objective: The aim of this study was to evaluate the comparability of twice-daily versus once-daily versions of the UAS and the resulting UAS7 values.

    Methods: Data came from the ASSURE-CSU study. Read More

    Basophils from allergic patients are neither hyper-responsive to activation signals nor hypo-responsive to inhibition signals.
    J Allergy Clin Immunol 2018 Jan 20. Epub 2018 Jan 20.
    Centre d'Immunologie Humaine, Département d'Immunologie, Institut Pasteur, Paris, France; Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, Inserm, CNRS, Marseille, France. Electronic address:
    Background: Basophil activation contributes to inflammatory reactions, especially in allergy. It is controlled, positively and negatively, by several mechanisms. High-affinity IgE receptors (FcεRI) generate a mixture of activation and inhibition signals upon aggregation, whose ratio depends on the concentration of allergen recognized by receptor-bound IgE. Read More

    Guideline-compliant prescription of biologicals and possible barriers in dermatological practices in Bavaria.
    J Eur Acad Dermatol Venereol 2018 Jan 22. Epub 2018 Jan 22.
    Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
    Introduction: Psoriasis and urticaria are chronic inflammatory skin diseases, which account for a substantial socioeconomic burden and severely affect patients' quality of life. According to the respective German guidelines, biologicals can be used for the treatment of severe forms of these diseases. However, only a minority of patients receive this advised treatment. Read More

    Molecular allergen profiling in horses by microarray reveals Fag e 2 from buckwheat as a frequent sensitizer.
    Allergy 2018 Jan 19. Epub 2018 Jan 19.
    The interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.
    Background: Companion animals are also affected by IgE-mediated allergies, but the eliciting molecules are largely unknown. We aimed at refining an allergen microarray to explore sensitization in horses and compare it to the human IgE reactivity profiles.

    Methods: Custom-designed allergen microarray was produced on the basis of the IimmunoCAP ISAC technology containing 131 allergens. Read More

    Biomarkers of treatment efficacy in patients with chronic spontaneous urticaria.
    Eur Ann Allergy Clin Immunol 2018 Jan;50(1):5-9
    Dermatology Service, Centro Médico de Caracas, Caracas, Venezuela.
    Summary: Currently there are no biomarkers useful to predict the future evolution and the therapeutic response in patients with chronic spontaneous urticaria (CSU).To review the available information on biomarkers that might be applied for the follow up of the response to guideline recommended therapies for CSU.A review of the medical literature on CSU potential clinical and laboratory biomarkers in PubMed and MEDLINE including the terms urticaria, chronic urticaria, chronic idiopathic urticaria, chronic spontaneous urticaria, antihistamines (AHs), omalizumab (OMA), cyclosporine (CyA), and treatment. Read More

    Clinicoepidemiologic Features of Chronic Urticaria in Patients with versus without Subclinical Helicobacter pylori Infection: A Cross-Sectional Study of 150 Patients.
    Int Arch Allergy Immunol 2018 Jan 19. Epub 2018 Jan 19.
    Department of Dermatology, Venereology and Leprosy, Dr. R.P. Govt. Medical College, Kangra, India.
    Background: The Helicobacter pylori infection is linked to chronic urticaria in nearly 60% of patients. We studied clinicoepidemiologic features in patients with chronic urticaria with and without H. pylori infection. Read More

    Does Problem Focused Coping Buffer the Effects of Trait Anxiety on Depressive Symptoms of Chronic Urticaria Patients?
    J Gen Psychol 2018 Jan-Mar;145(1):64-78. Epub 2018 Jan 18.
    d Haydarpaşa Sultan Abdülhamid Han Eğitim ve Araştırma Hastanesi , Division of Immunology and Allergy , Istanbul , Turkey.
    The present study examined the moderating role of problem-focused coping in trait anxiety-depressive symptoms' relationship in patients with chronic urticaria (CU). Eighty-eight CU patients, who applied to an outpatient clinic of Clinical Immunology and Allergic Diseases, filled out a questionnaire set including State-Trait Anxiety Inventory, Ways of Coping Inventory, and Beck Depression Inventory. The results suggested that CU patients high on trait anxiety reported more depressive symptoms, and the ones using more problem-focused coping (PFC) strategies reported less depressive symptoms. Read More

    Biological clocks: their relevance to immune-allergic diseases.
    Clin Mol Allergy 2018 10;16. Epub 2018 Jan 10.
    1Dipartimento di Medicina e Scienze dell'invecchiamento, Università "G. d'Annunzio" of Chieti-Pescara, Via dei Vestini, 5, 66013 Chieti, Italy.
    The 2017 Nobel Prize for Physiology or Medicine, awarded for the discoveries made in the past 15 years on the genetic and molecular mechanisms regulating many physiological functions, has renewed the attention to the importance of circadian rhythms. These originate from a central pacemaker in the suprachiasmatic nucleus in the brain, photoentrained via direct connection with melanopsin containing, intrinsically light-sensitive retinal ganglion cells, and it projects to periphery, thus creating an inner circadian rhythm. This regulates several activities, including sleep, feeding times, energy metabolism, endocrine and immune functions. Read More

    Successful Treatment of Autoimmune Urticaria with Low-Dose Prednisolone Therapy Administered for a Few Months: A Case Series of 42 Patients.
    Dermatology 2018 Jan 17. Epub 2018 Jan 17.
    Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
    Background: Chronic spontaneous urticaria (CSU) is defined as symptoms of urticaria persisting for 6 weeks or more without obvious cause. Autologous serum skin test (ASST) positivity in patients with CSU is considered to be associated with autoimmune urticaria (AIU).

    Methods: In this retrospective study we retrieved the medical records of 1,073 urticaria patients seen at the Department of Dermatology and Allergology of Szeged University between January 2005 and February 2014. Read More

    The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update.
    Allergy 2018 Jan 15. Epub 2018 Jan 15.
    Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology and Allergy, Allergy-Centre-Charité.
    This evidence and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on December 1st, 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. Read More

    Overweight and obesity may play a role in the pathogenesis of chronic spontaneous urticaria.
    Clin Exp Dermatol 2018 Jan 12. Epub 2018 Jan 12.
    Department of Internal Diseases, Allergology and Clinical Immunology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland.
    Background: Chronic spontaneous urticaria (CSU) is one of the commonest diseases in allergological and dermatological practice. It constitutes an interdisciplinary problem, and its pathogenesis is not always easily determined. It has been suggested that metabolic syndrome and hyperlipidaemia are more frequent in patients with CSU, but the influence of overweight and obesity on the development of CSU has not been thoroughly investigated. Read More

    [An atypical case of systemic juvenile idiopathic arthritis].
    Rev Med Brux 2017 ;38(6):511-514
    Service de Pneumologie pédiatrique, H.U.D.E.R.F., ULB.
    The systemic juvenile idiopathic arthritis (SJIA) is a rare, auto-inflammatory and chronic childhood disease. Arthritis of at least one joint is associated with a daily fever lasting more than two weeks and with one of the following signs: lymphadenopathy, hepatomegaly, serositis, or skin rash. Systemic symptoms are often initially preponderant, in the absence of arthritis than can occur weeks or months later. Read More

    The use of omalizumab in allergen immunotherapy.
    Clin Exp Allergy 2018 Jan 5. Epub 2018 Jan 5.
    Division of Pediatric Allergy and Immunology, Department of Pediatrics, John Hopkins University School of Medicine, Baltimore, MD, USA.
    Although omalizumab (anti-IgE) is currently only approved for the treatment of asthma and chronic idiopathic urticaria, it has also been studied as an off-label treatment for numerous allergic conditions, including use as an adjunct to allergen immunotherapy in the treatment of allergic rhinitis, asthma, venom hypersensitivity and food allergy. We conducted a review of publications involving the use of omalizumab with allergen immunotherapy, by searching PubMed with key search terms of "omalizumab" and "immunotherapy." Omalizumab has been used in combination with inhalant allergen immunotherapy for the treatment of seasonal allergic rhinitis and comorbid asthma. Read More

    In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional.
    Allergy 2018 Jan 9. Epub 2018 Jan 9.
    Charité - Universitätsmedizin Berlin, Department of Dermatology and Allergology, Berlin, Germany.
    Background: Chronic spontaneous urticaria (CSU) is a frequent disorder with recurrent itchy wheals and/or angioedema. Despite the known effectiveness of omalizumab therapy, the relevant IgE antigens are largely unknown. Recently, increased rates of elevated levels of IgE towards Staphylococcus aureus enterotoxins (SEs) were described in CSU. Read More

    Etiology of chronic urticaria: the Ecuadorian experience.
    World Allergy Organ J 2018 3;11(1). Epub 2018 Jan 3.
    Universidad Espíritu Santo, Km. 2.5 vía La Puntilla, Código postal: 0901-952 Samborondón, Ecuador.
    Background: The purpose of this study was to identify chronic urticaria (CU) etiologies and treatment modalities in Ecuador. We propose that the sample distribution fits the expected one, and that there is an association between the etiology and its treatment.

    Methods: We performed a retrospective study involving 112 patients diagnosed with CU using a Checklist for a complete chronic urticaria medical history. Read More

    Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab.
    J Asthma 2018 Jan 4:1-3. Epub 2018 Jan 4.
    a Department of Internal Medicine , Jagiellonian University Medical College , Krakow , Poland.
    Asthma therapy with monoclonal antibodies is a promising and effective approach for those with a severe and refractory type of disease. Although such a targeted therapy is considered to be safe, unusual complications may occur. We present a case of a 45 year-old female patient with severe allergic asthma and chronic spontaneous urticaria, who developed autoimmune polyendocrine syndrome type 2 (APS-2) after 26 months of omalizumab administration. Read More

    Amelioration of patients with chronic spontaneous urticaria in treatment with vitamin D supplement.
    Clin Mol Allergy 2017 22;15:22. Epub 2017 Dec 22.
    Allergy Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Shariati Square, Mashhad, Iran.
    Background: Spontaneous urticaria is a common allergic skin condition affecting 0.5-1% of individuals and may burden on health care expenditure or may be associated with remarkable morbidity.

    Aim: In this study, we measured the effect of vitamin D supplementation in patients with a diagnosis of CSU. Read More

    Gene mutations and clinical phenotypes in 15 Chinese children with cryopyrin-associated periodic syndrome (CAPS).
    Sci China Life Sci 2017 Dec 2;60(12):1436-1444. Epub 2017 Dec 2.
    Department of Rheumatology and Immunology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
    The aim of our study is to explore the features of clinical manifestations and genetic mutations in Chinese CAPS patients. Fifteen confirmed patients with CAPS were enrolled. The onset time ranges from 2 days after birth to 6 years and 1 month. Read More

    Elevated circulating heat shock protein 70 and its antibody concentrations in chronic spontaneous urticaria.
    Int J Immunopathol Pharmacol 2017 Dec 1:394632017750440. Epub 2017 Dec 1.
    1 Department of Internal Diseases, Dermatology and Allergology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland.
    Heat shock proteins (Hsp) play a complex role in cytoprotection, inflammation, and function of the immune system. They may be involved in pathogenesis of various diseases. Our aim was to determine circulating Hsp70 and anti-Hsp70 antibodies concentrations in patients with chronic spontaneous urticaria (CSU). Read More

    Obesity is not associated with severe chronic urticaria in a French cohort.
    J Eur Acad Dermatol Venereol 2017 Dec 19. Epub 2017 Dec 19.
    Department of Cardiology, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

    Effectiveness and Safety of the Combination of the Traditional Chinese Medicine Prescription Jade Screen and Desloratadine in the Treatment of Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Evid Based Complement Alternat Med 2017 12;2017:1390301. Epub 2017 Nov 12.
    Dermatological Department, The Second Affiliated Hospital of Baotou Medical College, No. 30 Hudemulin Road, Baotou, Inner Mongolia 014030, China.
    Objective: The aim of this study is to systematically evaluate the clinical efficacy and safety of the traditional Chinese medicine prescription Jade Screen combined with desloratadine in the treatment of chronic urticaria.

    Methods: Two researchers independently conducted literature searches. The extracted data were analyzed using Rev Man 5. Read More

    Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria.
    Sci Rep 2017 Dec 19;7(1):17797. Epub 2017 Dec 19.
    Department of Dermatology, Affiliated Hospital of Ningbo University School of Medicine, Ningbo, 315020, China.
    Chronic spontaneous urticaria (CSU) is considered in a subset of patients to be an autoimmune disorder. Interleukin(IL)-17, IL-31, and IL-33 are involved in some immune response. The aim of this study was to quantify plasma IL-17, IL-31, and IL-33 levels in CSU patients and to examine their relationships with disease severity. Read More

    Elevated plasma il-8 concentration is related to severity of systemic inflammation in chronic spontaneous urticaria.
    J Biol Regul Homeost Agents 2017 Oct-Dec;31(4):957-961
    Department of Internal Diseases, Dermatology and Allergology in Zabrze, SMDZ in Zabrze, Medical University of Silesia in Katowice, Poland.
    Chronic spontaneous urticaria (CSU) is associated with activation of acute phase response. Questions arise regarding its association with other inflammatory mediators. To determine plasma IL-8 concentration in CSU patients and its association with C-reactive protein (CRP) concentration, a nonspecific inflammatory marker of the disease activity, concentrations of plasma IL-8 and serum CRP were measured in CSU patients and compared with healthy controls. Read More

    Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis.
    Eur Ann Allergy Clin Immunol 2017 Nov;49(6):286-287
    Allergy Department, "Sotiria" General Hospital, Athens, Greece.
    Summary: Data derived from previous clinical trials and real-life studies have shown that omalizumab may represent an effective third-line treatment option for patients with chronic spontaneous urticaria (CSU) refractory to standard antihistamine treatment. Nevertheless, the safety and efficacy of omalizumab treatment for CSU, when administered concurrently with other immunomodulatory agents remains largely unknown. We herein present the case of a female patient with relapsing-remitting multiple sclerosis (RRMS), under treatment with interferon beta-1a, azathioprine and gabapentin, who was successfully treated with omalizumab for refractory CSU. Read More

    1 OF 89